Matthias Mayerhofer
Overview
Explore the profile of Matthias Mayerhofer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1711
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greiner G, Witzeneder N, Klein K, Tangermann S, Kodajova P, Jaeger E, et al.
Blood
. 2023 Dec;
143(11):1006-1017.
PMID: 38142424
Systemic mastocytosis (SM) is defined by the expansion and accumulation of neoplastic mast cells (MCs) in the bone marrow (BM) and extracutaneous organs. Most patients harbor a somatic KIT D816V...
2.
Mayerhofer E, Ratzinger F, Kienreich N, Stiel A, Witzeneder N, Schrefl E, et al.
Front Pediatr
. 2020 Mar;
8:52.
PMID: 32154197
Childhood obesity is an increasing health care problem associated with insulin resistance and low-level systemic inflammation, which can ultimately lead to diabetes. Evidence for efficacy of therapeutic intervention programs on...
3.
Greiner G, Gurbisz M, Ratzinger F, Witzeneder N, Class S, Eisenwort G, et al.
Haematologica
. 2019 Apr;
105(2):366-374.
PMID: 31018976
A high allele burden of the D816V mutation in peripheral blood or bone marrow aspirates indicates multi-lineage hematopoietic involvement and has been associated with an aggressive clinical course of systemic...
4.
Greiner G, Gurbisz M, Ratzinger F, Witzeneder N, Simonitsch-Klupp I, Mitterbauer-Hohendanner G, et al.
Clin Chem
. 2017 Dec;
64(3):547-555.
PMID: 29237714
Background: The analytically sensitive detection of D816V in blood and bone marrow is important for diagnosing systemic mastocytosis (SM). Additionally, precise quantification of the D816V variant allele fraction (VAF) is...
5.
CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis
Greiner G, Witzeneder N, Berger A, Schmetterer K, Eisenwort G, Schiefer A, et al.
Blood
. 2016 Nov;
129(3):371-382.
PMID: 27856463
Systemic mastocytosis (SM) is characterized by abnormal accumulation of neoplastic mast cells harboring the activating KIT mutation D816V in the bone marrow and other internal organs. As found in other...
6.
Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott R, et al.
Cancer Cell
. 2016 Aug;
30(2):359-360.
PMID: 27505678
No abstract available.
7.
Blatt K, Cerny-Reiterer S, Schwaab J, Sotlar K, Eisenwort G, Stefanzl G, et al.
Blood
. 2015 Oct;
126(26):2832-41.
PMID: 26486787
The Ki-1 antigen (CD30) is an established therapeutic target in patients with Hodgkin lymphoma and anaplastic large-cell lymphoma. We have recently shown that CD30 is expressed abundantly in the cytoplasm...
8.
Grunt T, Hebar A, Laffer S, Wagner R, Peter B, Herrmann H, et al.
Am J Cancer Res
. 2015 May;
5(2):560-74.
PMID: 25973297
Advanced colorectal cancer is characterized by uncontrolled growth and resistance against anti-cancer agents, including ErbB inhibitors. Recent data suggest that cancer stem cells (CSC) are particularly resistant. These cells may...
9.
Blatt K, Herrmann H, Hoermann G, Willmann M, Cerny-Reiterer S, Sadovnik I, et al.
Clin Cancer Res
. 2014 May;
20(13):3589-602.
PMID: 24799522
Purpose: The CD52-targeted antibody alemtuzumab induces major clinical responses in a group of patients with myelodysplastic syndromes (MDS). The mechanism underlying this drug effect remains unknown. Experimental Design: We asked...
10.
Herrmann H, Sadovnik I, Cerny-Reiterer S, Rulicke T, Stefanzl G, Willmann M, et al.
Blood
. 2014 Apr;
123(25):3951-62.
PMID: 24778155
Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are well-defined, little is known about effector-molecules contributing to malignant...